Clinical trials: Insulin Dependent Diabetes
Diabetes Mellitus, Type 1
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
The purpose of this study is to assess the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety of 3 milligrams (mg) glucagon (glucagon nasal powder) administered nasally compared with commercially available…
- Trial name
- NCT01994746
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 8 sites in United States
- Volunteers
- 77 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes
This trial was conducted in Europe. The aim of this study was to investigate the total exposure of NN5401 (insulin degludec/insulin aspart) in children, adolescents and adult subjects with type 1 diabetes.
- Trial name
- NCT01138488
- Testing
- insulin degludec/insulin aspart
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes.
- Trial name
- ADJUNCT ONE™ (NCT01836523)
- Testing
- liraglutide
- Where
- 182 sites in United States, Argentina and 15 more
- Volunteers
- 1,398 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Diabetes Mellitus
Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes
The purpose of this study is to assess safety and tolerability and determine the pharmacokinetics of subcutaneous single and multiple (up to 12) dose administration of CBX129801 (long-acting synthetic C-peptide) in type 1…
- Conditions
- Type 1 Diabetes, Diabetes Mellitus, Peripheral Diabetic Neuropathy
- Trial name
- NCT01293461
- Testing
- CBX129801
- Where
- 8 sites in United States
- Volunteers
- 72 people
- Sponsor
- Cebix Incorporated
Type 1 Diabetes Mellitus
A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus
The main purpose of this study is to evaluate the effect of excipients sodium citrate and treprostinil without insulin on local infusion site pain in participants with type 1 diabetes mellitus (T1DM) on continuous subcutaneous…
- Trial name
- NCT05067270
- Testing
- Sodium Citrate, Treprostinil, Humalog diluent
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
Type I Diabetes
Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes
Objectives Primary study objective: To determine whether orally-administered ladarixin versus placebo adjunctive therapy improves insulin sensitivity in overweight, insulin-resistant (IR) type 1 Diabetic (T1D) adult subjects.
- Trial name
- NCT05035368
- Testing
- Ladarixin
- Where
- United States
- Sponsor
- Dompé Farmaceutici S.p.A
Diabetes Mellitus, Diabetes Mellitus ( Type 1 and Type 2)
PMCF Study of GX-01S CGM in Adults With Diabetes
This clinical study evaluates the GX-01S Continuous Glucose Monitoring (CGM) System in adults with Type 1 or Type 2 diabetes. CGM systems measure glucose levels continuously throughout the day, providing real-time information…
- Trial name
- PROMISE-GX (NCT07802327)
- Testing
- GX-01S Continuous Glucose Monitoring System
- Volunteers
- 100 people
- Sponsor
- MicroTech Medical（Hangzhou）Co.,Ltd.
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
Examine the effects of TI in combination with an anti-diabetic regimen including inhaled insulin versus anti-diabetic treatment without inhaled insulin on lung function \& pulmonary safety
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Moderate Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT00642616
- Testing
- Technosphere® Insulin, Usual Care
- Where
- 21 sites in United States, Russia and 1 more
- Volunteers
- 34 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus ( Type 1 and Type 2), Hypertension
Care COMPASS Study
This is a prospective, single-arm, mixed-methods pilot study at a single academic medical center to observe the impact, feasibility and acceptability of an AI Care Companion tool on activation and confidence among patients with…
- Trial name
- NCT07904793
- Testing
- Guide My Care Tool
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Fitbit LLC
Diabetes Mellitus, Type 1
A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System
The main objective is to determine the feasibility of dasiglucagon in a bi-hormonal reactive closed loop system for automated glucose regulation (artificial pancreas; AP®) in patients with diabetes mellitus type 1.
- Trial name
- STABLE-1 (NCT05454709)
- Testing
- Dasiglucagon, GlucaGen
- Where
- Netherlands
- Sponsor
- Inreda Diabetic B.V.
Diabetes, Diabetes Mellitus, Type 1 Diabetes
Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device
The purpose of this study is to collect information about Fiasp® to evaluate how effective Fiasp® is in treating elevated blood sugar in patients with type 1 diabetes, compared with the participant's previous insulin treatment.
- Trial name
- GoBolus (NCT03450863)
- Testing
- Fast-acting insulin aspart
- Where
- Germany
- Volunteers
- 320 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps
This study evaluates a new test formulation of a glucose lowering drug, insulin lispro, delivered by an insulin pump continuously under the skin.
- Trial name
- NCT02623478
- Testing
- Insulin Lispro
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)
The purpose of this study is to assess the effects of administration of canagliflozin 100 mg and 300 mg, compared with placebo as an addition to insulin therapy for the treatment of Type 1 Diabetes Mellitus (T1DM).
- Trial name
- NCT02139943
- Testing
- Canagliflozin 100 mg, Canagliflozin 300 mg
- Where
- 53 sites in United States, Canada
- Volunteers
- 352 people
- Sponsor
- Janssen Research & Development, LLC
Type 1 Diabetes Mellitus
New Glucose Sensor Pediatric
The purpose of this study is to assess performance of a new subcutaneous glucose sensor over a seven day sensor life when used with currently marketed Medtronic Diabetes devices.
- Trial name
- NCT01161043
- Testing
- Sensor wear
- Where
- 4 sites in United States
- Volunteers
- 83 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus
Use of the Guardian™ Connect System With Smart Connected Devices
The purpose of this study is to collect sensor, insulin, sleep, activity and food/meal data for a minimum of 90 days of device wear (Phase 1) and up to a maximum of 9 months of device wear (Phase 2) with optional insulin…
- Trial name
- NCT04809285
- Testing
- Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app
- Where
- 14 sites in United States
- Volunteers
- 217 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus
Safety and Performance Evaluation of the SAVA Continuous Glucose Monitor for Effective Glucose Detection
The goal of this clinical trial is to evaluate the safety and performance of the SAVA Continuous Glucose Monitor across glucose ranges over a period of 15-day wear in adults over 18 years of age with Type 1 Diabetes.
- Trial name
- SPEED (NCT07679347)
- Testing
- CGM Devices
- Volunteers
- 20 people
- Sponsor
- SAVA Technologies Ltd.
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
The purpose of this study is to check that a new insulin pump, called NMX8, is safe when used with a continuous glucose monitoring sensor called Disposable Sensor 5/Simplera Sync in people with diabetes.
- Trial name
- NCT07228117
- Testing
- MiniMed™ NMX8-AID System with DS5™/Simplera Sync™
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 389 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Insulin-Dependent
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes
The objective of this clinical trial is to investigate whether ladarixin has sufficient activity (preservation of β-cell function and slow-down of the progression of T1D) to warrant its further development (proof of concept…
- Trial name
- NCT02814838
- Testing
- Ladarixin
- Where
- 8 sites in Belgium, Germany and 1 more
- Volunteers
- 76 people
- Sponsor
- Dompé Farmaceutici S.p.A
Diabetes Mellitus, Type 1
Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
Placebo-controlled, double blind (triple-dummy technique), randomised parallel design comparison of three oral doses (2.5 mg, 10 mg, and 25 mg) of empagliflozin in patients with T1DM as adjunctive therapy to insulin over 28 days.
- Trial name
- NCT01969747
- Testing
- Empagliflozin medium, Empagliflozin low
- Where
- 2 sites in Austria, Germany
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes, Nephropathy
A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)
Evaluate the effect of Losartan in reducing kidney disease in patients with Non-insulin Dependent Diabetes and Nephropathy (kidney damage that usually accompanies late stage Diabetes Mellitus).
- Trial name
- NCT00308347
- Testing
- MK0954, losartan / Duration of Treatment: mean 3.4 years
- Volunteers
- 1,513 people
- Sponsor
- Organon and Co
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.